RxDoctor Payments Data

Derek Smith

Gerontology · Houston, TXNPI 1669908802

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.7% of the total across 410 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Gilead at 34.5% of the total. Among gerontology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,595in general payments, 2019–2025

Across 410 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • Viiv Healthcare Company$2K
  • Napo Pharmaceuticals Inc$630
  • Johnson & Johnson$624
  • Merck$620
  • Antares Pharma, Inc.$190
  • plus $1K from 17 others
$1,367in research payments, 2019–2025

Across 9 payments — averaging $151.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K

What the payments were for

  • Speaking & faculty fees$3885%
  • Food & beverage$8,05794%
  • Education$1502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,595 in reported general payments places this provider in the 95th percentile of 653 gerontology providers in Texas.

See all gerontology providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala53$223,621
DescovyEmtricitabine/Tenofov Alafenam27$61,079
PrezcobixDarunavir/Cobicistat13$32,084
Isentress HdRaltegravir Potassium14$28,105
OzempicSemaglutide19$19,396
MounjaroTirzepatide14$14,939
XyostedTestosterone Enanthate12$7,740
ValacyclovirValacyclovir Hcl29$1,648
Testosterone Cypionate18$1,082
Rosuvastatin Calcium23$297
Omeprazole14$284
Temazepam11$264
Quetiapine Fumarate18$209
Montelukast Sodium11$199
Lisinopril16$195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$2,966$284,69980 claims
Johnson & JohnsonPrezcobix$624$32,08413 claims
MerckIsentress Hd$620$28,10514 claims
Novo NordiskOzempic$182$19,39619 claims
Lilly USA, LLCMounjaro$88$14,93914 claims
Antares Pharma, Inc.Xyosted$190$7,74012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 gerontology providers in Texas.

Other gerontology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →